Overview

A Phase 2, Randomized, Placebo-controlled, Double-blind Study of EG017 in Female Patients With Stress Urinary Incontinence

Status:
Completed

Trial end date:
2022-09-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether EG017 is safe and effective in the treatment of stress urinary incontinence in postmenopausal women.

Phase:

Phase 2

Details

Lead Sponsor:

GeneScience Pharmaceuticals Co., Ltd.

Collaborator:

Peking University People's Hospital